Letters
Drug firm conflicting interests
Radical change, not tweaking, is needed
BMJ 2009; 339 doi: https://doi.org/10.1136/bmj.b5656 (Published 31 December 2009) Cite this as: BMJ 2009;339:b5656
- John H Noble Jr, emeritus professor1
- 1State University of New York at Buffalo
- jhnoble{at}verizon.net
Lawton makes the case against major reform of the way the pharmaceutical and medical device industry currently does business against Goldacre’s call for the conduct of clinical trials by disinterested third parties to offset the inherent biases of industry sponsored clinical trials.1 2 He dismisses Goldacre’s argument that …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.